Hippo Pathway-mediated YAP1/TAZ Inhibition is Essential for Proper Pancreatic Endocrine Specification and Differentiation
Authors
Affiliations
The Hippo pathway plays a central role in tissue development and homeostasis. However, the function of Hippo in pancreatic endocrine development remains obscure. Here, we generated novel conditional genetically engineered mouse models to examine the roles of Hippo pathway-mediated YAP1/TAZ inhibition in the development stages of endocrine specification and differentiation. While YAP1 protein was localized to the nuclei in bipotent progenitor cells, Neurogenin 3 expressing endocrine progenitors completely lost YAP1 expression. Using genetically engineered mouse models, we found that inactivation of YAP1 requires both an intact Hippo pathway and Neurogenin 3 protein. Gene deletion of Lats1 and 2 kinases () in endocrine progenitor cells of developing mouse pancreas using blocked endocrine progenitor cell differentiation and specification, resulting in reduced islets size and a disorganized pancreas at birth. Loss of in Neurogenin 3 expressing cells activated YAP1/TAZ transcriptional activity and recruited macrophages to the developing pancreas. These defects were rescued by deletion of genes, suggesting that tight regulation of YAP1/TAZ by Hippo signaling is crucial for pancreatic endocrine specification. In contrast, deletion of using β-cell-specific Ins1 resulted in a phenotypically normal pancreas, indicating that are indispensable for differentiation of endocrine progenitors but not for that of β-cells. Our results demonstrate that loss of YAP1/TAZ expression in the pancreatic endocrine compartment is not a passive consequence of endocrine specification. Rather, Hippo pathway-mediated inhibition of YAP1/TAZ in endocrine progenitors is a prerequisite for endocrine specification and differentiation.
Rosas P, Solaro R Compr Physiol. 2025; 15(2):e70006.
PMID: 40065530 PMC: 11894248. DOI: 10.1002/cph4.70006.
Pancreatic endocrine and exocrine signaling and crosstalk in physiological and pathological status.
Hu C, Chen Y, Yin X, Xu R, Yin C, Wang C Signal Transduct Target Ther. 2025; 10(1):39.
PMID: 39948335 PMC: 11825823. DOI: 10.1038/s41392-024-02098-3.
Zhou L, Zhang X, Zhang C, Wang Y, Zhang J, Wang Y Cytojournal. 2025; 21:66.
PMID: 39917005 PMC: 11801646. DOI: 10.25259/Cytojournal_91_2024.
Wu Y, Qin K, Xu Y, Rajhans S, Vo T, Lopez K Elife. 2024; 13.
PMID: 39051998 PMC: 11272159. DOI: 10.7554/eLife.84532.